Navigation Links
Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
Date:5/12/2010

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

About Bladder Cancer

According to the National Cancer Institute, bladder cancer is the sixth most common type of cancer. In 2009, there were 70,980 new cases and 14,330 deaths from bladder cancer in the U.S. alone.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of b
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... CA, and Bellingham, WA (PRWEB) August 26, 2014 ... optical engineering, visions for next-generation wearable technology, and ... among numerous highlights at this year’s brighter, busier ... San Diego, California, Convention Center. More than 4,400 ... week attended conferences, courses, an exhibition, and industry ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 The 20 ... of ALS (YFALS) community issued the following statement on ... bringing awareness and driving new funding specifically for ALS ... of water and some ice would raise all this ... with our families, and on behalf of the entire ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... strains in Pubmed, has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
Breaking Biology Technology:Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Competition for graphene 2
... Corporation (NASDAQ: LIFE ) today announced it ... Conference on Tuesday, September 20 at 8:00am ET.  Greg ... present on behalf of the company. The company will ... weeks following the conference on the Life Technologies, investor ...
... Aug. 29, 2011 Chemical Abstracts Service ( CAS ... that Syngene International , an internationally reputed contract ... biotechnology company, has signed a three-year contract to provide ... award-winning chemistry research tool. SciFinder offers ...
... 26, 2011 Quantum Learning, Inc. (QLI), ... programs, and Jay Elliot, author of the book " ... announced today a licensing agreement.  Under the terms of ... training program called "Market-Leading Innovation™ (The path to Innovation ...
Cached Biology Technology:Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 3Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 2Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 3
(Date:8/26/2014)... has recommended investing in dog owner education and facilities as ... obesity in both people and their pets. , In a ... that access to dog-friendly walking environments and better education about ... and take more exercise with their pets. , It is ... for a walk. In the UK, almost a quarter of ...
(Date:8/25/2014)... biofuels industry: "You can make anything from lignin ... pave the way to challenging that adage. The ... Laboratory (NREL) demonstrates a concept that provides opportunities ... variety of renewable fuels, chemicals, and materials for ... Through Integrated Biological Funneling and Chemical Catalysis " ...
(Date:8/25/2014)... A family of proteins that promotes virus entry ... release of HIV and other viruses, University of Missouri ... that provides new insights into our understanding of not ... other viruses," said Shan-Lu Liu, M.D., Ph.D., associate professor ... Microbiology and Immunology. , The study was recently published ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... and interact with human cells has been identified. This ... a recent collaborative study carried out by the University ... Finland. The findings increase our understanding of the strategies ... further facilitates the development of baculovirus for applications of ...
... of Virginia engineering professor has proposed a novel approach ... , Andres Clarens, an assistant professor of civil and ... Science, and graduate student Zhiyuan Tao have published a ... dioxide that could be stored in hydraulically fractured shale ...
... A new urine test for prostate cancer that measures ... men nationwide through the University of Michigan MLabs. The ... blood test, increases physicians, ability to pick out high-risk ... help tens of thousands of men avoid unnecessary biopsies. ...
Cached Biology News:U.Va. researcher: Methane out, carbon dioxide in? 2Prostate Cancer Foundation announces new urine test for prostate cancer available 2Prostate Cancer Foundation announces new urine test for prostate cancer available 3
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... Immunogen corresponds to amino acids 2-105 from ... been successfully used in Western blot, immunocytochemistry ... this antibody detects an ~ 60 kDa ... also been used in immunoprecipitation and immunocytochemical ...
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
Biology Products: